Aetna modified CPB 0474 for total body plethysmography, effective September 26, 2025. Here's what billing teams need to know before claims go out the door.
Aetna, a CVS Health company, updated its total body plethysmography coverage policy under CPB 0474 in Aetna's clinical policy bulletin system. The primary covered code is CPT 94726 (plethysmography for determination of lung volumes and airway resistance), and coverage depends on meeting one of six specific medical necessity indications. If your pulmonology, respiratory therapy, or hospital outpatient billing team submits CPT 94726 for Aetna members, this update directly shapes whether those claims pay or deny.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Total Body Plethysmography |
| Policy Code | CPB 0474 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Pulmonology, Respiratory Therapy, Hospital Outpatient, Internal Medicine |
| Key Action | Audit CPT 94726 claims to confirm documentation maps to one of the six covered indications before submitting to Aetna |
Aetna Total Body Plethysmography Coverage Criteria and Medical Necessity Requirements 2025
The Aetna total body plethysmography coverage policy is narrow and specific. Aetna covers CPT 94726 only as an adjunct to complete pulmonary function testing — meaning it must accompany residual volume measurement and diffusion testing. You cannot bill it as a standalone procedure and expect payment.
Medical necessity for CPT 94726 requires that the clinical scenario fit one of six indications. These are not loose guidelines. They are the policy's actual criteria, and claim denial risk is high when documentation doesn't clearly match them.
The six covered indications are:
| # | Covered Indication |
|---|---|
| 1 | Bronchial hyper-reactivity testing. The patient is undergoing determination of bronchial hyper-reactivity in response to methacholine, histamine, or isocapnic hyperventilation. If your provider is running a methacholine challenge, CPT 94726 is appropriate here when it's part of complete PFTs. |
| 2 | Bronchodilator response — FEV1 discordance. The patient shows a clinical response to bronchodilators but does not show an improvement in FEV1 by spirometry. This is the scenario where the patient clearly feels better but the spirometry numbers don't move. Plethysmography fills the measurement gap. |
| 3 | Obstructive lung disease with measurement artifact risk. The patient has bullous emphysema, cystic fibrosis (ICD-10-CM E84.0–E84.19 range), or a similar obstructive disease that may produce artificially low results by helium dilution or nitrogen washout. Plethysmography avoids that artifact. |
| 4 | Airflow resistance calculation. The patient has an obstructive process and accurate calculation of true lung volumes requires plethysmography. Standard spirometry isn't enough here — the clinical note needs to say why. |
| 5 | Restrictive vs. obstructive distinction. A spirometry test shows low vital capacity (below 80% predicted), and the provider needs to determine whether the process is restrictive or obstructive. This is one of the most common clinical scenarios where CPT 94726 gets ordered — make sure the spirometry result and the clinical rationale are in the documentation before you bill. |
| 6 | Multiple trials or inability to perform multi-breath tests. The patient requires multiple repeated trials, or the patient cannot perform multi-breath tests. Document the specific reason. |
None of these indications require prior authorization to be listed explicitly in the policy. However, given that Aetna flags medical necessity criteria this specifically, check your plan-level requirements. Some Aetna commercial and Medicare Advantage plans layer prior authorization requirements on top of the clinical policy bulletin. If your Aetna volume is significant and you're unsure, talk to your compliance officer before the September 26, 2025 effective date.
The reimbursement exposure here is real. CPT 94726 carries meaningful relative value — and if your documentation doesn't map to an indication, you're looking at denial and potential write-off.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Bronchial hyper-reactivity (methacholine, histamine, isocapnic hyperventilation) | Covered | CPT 94726 | Must be adjunct to complete PFTs including residual volumes and diffusion |
| Bronchodilator response with clinical improvement but no FEV1 change on spirometry | Covered | CPT 94726 | Document clinical response and spirometry result clearly |
| Obstructive lung disease (bullous emphysema, cystic fibrosis) with artifact risk from helium dilution or nitrogen washout | Covered | CPT 94726, ICD-10 E84.0–E84.19 | Note why alternative methods produce artifactual results |
| Airflow resistance evaluation in obstructive process requiring true lung volume calculation | Covered | CPT 94726 | Specify why plethysmography is necessary for accurate calculation |
| Low vital capacity (<80% predicted on spirometry) — distinguishing restrictive from obstructive | Covered | CPT 94726 | Spirometry result must be documented; VC <80% predicted is the threshold |
| Multiple repeated trials required or patient unable to perform multi-breath tests | Covered | CPT 94726 | Document reason for multiple trials or inability to perform test |
Aetna Total Body Plethysmography Billing Guidelines and Action Items 2025
These steps apply to your billing team starting September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your CPT 94726 charge capture documentation now. Before September 26, 2025, pull a sample of recent CPT 94726 claims billed to Aetna. Check whether the clinical notes specify which of the six indications the test was ordered to address. Vague documentation like "PFTs ordered for SOB" doesn't support medical necessity under this coverage policy. |
| 2 | Confirm CPT 94726 is always billed as an adjunct, not standalone. The policy requires CPT 94726 to accompany complete pulmonary function testing that includes residual volumes and diffusion. If your claim shows CPT 94726 without the accompanying PFT codes, you're exposed. Update your billing guidelines internally to flag standalone submissions. |
| 3 | Map your ICD-10-CM diagnosis codes to the clinical indication. For cystic fibrosis cases, use the appropriate E84.x code. For sarcoidosis, use D86.x. Your ICD-10 diagnosis code should directly support the plethysmography indication in the chart. A diagnosis code alone doesn't create medical necessity — but a mismatch between diagnosis and indication is a fast path to denial. |
| 4 | Check plan-level prior authorization requirements separately. CPB 0474 sets the clinical criteria, but individual Aetna plan contracts — especially Medicare Advantage and some self-insured commercial plans — may require prior authorization for CPT 94726 regardless of the CPB. Don't assume the absence of a PA requirement in the CPB means no PA is needed. Verify at the plan level before scheduling. |
| 5 | Train your clinical documentation team on the FEV1 discordance scenario. Indication two (clinical bronchodilator response without FEV1 improvement) is commonly under-documented. Providers know the clinical picture but don't always write it down explicitly. If a patient clearly responds to a bronchodilator but the spirometry doesn't budge, that clinical reasoning needs to appear in the note — not just the test results. |
| 6 | Set an internal reminder for claims submitted after September 26, 2025. If you're submitting CPT 94726 claims dated on or after the effective date, your documentation standard needs to meet the updated CPB 0474 criteria. Flag this date in your revenue cycle calendar now. |
If your practice or facility bills significant volume of pulmonary function testing to Aetna members and you're not confident your current documentation process covers these six indications, loop in your billing consultant or compliance officer before September 26.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Total Body Plethysmography Under CPB 0474
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 94726 | CPT | Plethysmography for determination of lung volumes and, when performed, airway resistance |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D86.0 | Sarcoidosis of lung |
| D86.1 | Sarcoidosis of lymph nodes |
| D86.2 | Sarcoidosis of lung with sarcoidosis of lymph nodes |
| D86.3 | Sarcoidosis of skin |
| D86.4 | Sarcoidosis of liver |
| D86.5 | Sarcoidosis of other specified sites |
| D86.6 | Sarcoidosis of parotid gland and lacrimal gland |
| D86.7 | Sarcoidosis of other and combined sites |
| D86.8 | Sarcoidosis NEC |
| D86.9 | Sarcoidosis, unspecified |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| E84.1 | Cystic fibrosis with intestinal manifestations |
| E84.2 | Cystic fibrosis with other manifestations |
| E84.3 | Cystic fibrosis, other |
| E84.4 | Cystic fibrosis, other |
| E84.5 | Cystic fibrosis, other |
| E84.6 | Cystic fibrosis, other |
Get the Full Picture for CPT 94726
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.